Antagonist activity of the antipsychotic drug lithium chloride and the antileukemic drug imatinib mesylate during glioblastoma treatment in vitro

Aras Y., ERGÜVEN M., Aktas E., YAZIHAN N., Bilir A.

NEUROLOGICAL RESEARCH, vol.38, no.9, pp.766-774, 2016 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 38 Issue: 9
  • Publication Date: 2016
  • Doi Number: 10.1080/01616412.2016.1203096
  • Journal Name: NEUROLOGICAL RESEARCH
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.766-774
  • Keywords: Imatinib mesylate, Lithium chloride, Midkine, Glioblastoma, Antagonism, BETA-CATENIN, MIDKINE, INHIBITION, EXPRESSION, AUTOPHAGY, ACTIVATION, MECHANISMS, ARREST
  • Ankara University Affiliated: Yes

Abstract

Objectives: Glioblastoma (GBM), the most common primary tumour of the central nervous system, is characterised by a high malignancy and poor prognosis. The aims of this study were to investigate whether the combination of imatinib mesylate (IM) and lithium chloride (LiCl) exhibited a synergistic effect in treatment and to determine whether midkine (MK) affected the fate of this treatment in vitro.